CONFIRMED
uBiome and the Gut-Test Startup That Billed Its Way to a Billion
uBiome arrived with one of the most appealing pitches of the health-technology boom: that by sequencing the trillions of microbes living in your gut — your microbiome — it could unlock insights into your health, from digestion to mood to disease, and put the power of cutting-edge genomics into the hands of ordinary consumers. Founded in San Francisco in 2012, it rode a genuine wave of scientific excitement about the microbiome, raised tens of millions of dollars from prominent venture capitalists, was hailed as a rising star of the gut-health revolution, and reached a valuation approaching a billion dollars. But beneath the science-forward image was a business model that, federal prosecutors would allege, was substantially a fraud — not in the technology so much as in the billing. To turn its consumer curiosity-kit into real revenue, uBiome had pushed its tests into the medical system and billed health insurers aggressively and improperly for them: ordering tests that were not medically necessary, billing for the same samples more than once, and using doctors who were not genuinely independent to authorise the orders. The company's revenue, the case suggested, came less from a breakthrough in health than from a scheme to extract money from insurers. In April 2019 the FBI raided uBiome's offices; the founders were placed on leave and then departed; the company filed for bankruptcy within months; and the two co-founders were ultimately charged with fraud. This article tells the story of uBiome — a quieter, more technical cautionary tale than its famous cousins, but in some ways a more revealing one, because its fraud was hidden not in a fake machine or a missing billion but in the mundane, lucrative mechanics of medical billing.
